| FragLites-minimal, halogenated fragments displaying pharmacophore doublets. An efficient approach to druggability assessment and hit generation. D Wood, JD Lopez-Fernandez, L Knight, I Al-Khawaldeh, C Gai, S Lin, ... Journal of medicinal chemistry, 2019 | 83 | 2019 |
| Investigation of the effect of molecular properties on the binding kinetics of a ligand to its biological target DC Miller, G Lunn, P Jones, Y Sabnis, NL Davies, P Driscoll MedChemComm 3 (4), 449-452, 2012 | 62 | 2012 |
| Discovery of potent & selective inhibitors of activated thrombin-activatable fibrinolysis inhibitor for the treatment of thrombosis ME Bunnage, J Blagg, J Steele, DR Owen, C Allerton, AB McElroy, ... Journal of medicinal chemistry 50 (24), 6095-6103, 2007 | 54 | 2007 |
| Structure-Based Design of Potent and Orally Active Isoindolinone Inhibitors of MDM2-p53 Protein–Protein Interaction G Chessari, IR Hardcastle, JS Ahn, B Anil, E Anscombe, RH Bawn, ... Journal of Medicinal Chemistry 64 (7), 4071-4088, 2021 | 34 | 2021 |
| Optimising metabolic stability in lipophilic chemical space: the identification of a metabolically stable pyrazolopyrimidine CRF-1 receptor antagonist DC Miller, W Klute, A Calabrese, AD Brown Bioorganic & medicinal chemistry letters 19 (21), 6144-6147, 2009 | 24 | 2009 |
| Identification of a novel orally bioavailable ERK5 inhibitor with selectivity over p38α and BRD4 SM Myers, DC Miller, L Molyneux, M Arasta, RH Bawn, TJ Blackburn, ... European journal of medicinal chemistry 178, 530-543, 2019 | 22 | 2019 |
| Discovery of potent, metabolically stable purine CRF-1 antagonists with differentiated binding kinetic profiles DC Miller, W Klute, AD Brown Bioorganic & medicinal chemistry letters 21 (20), 6108-6111, 2011 | 21 | 2011 |
| SAR mining and its application to the design of TRPA1 antagonists JEJ Mills, AD Brown, T Ryckmans, DC Miller, SE Skerratt, CM Barker, ... MedChemComm 3 (2), 174-178, 2012 | 20 | 2012 |
| Efficacious N-protection of O-aryl sulfamates with 2, 4-dimethoxybenzyl groups T Reuillon, A Bertoli, RJ Griffin, DC Miller, BT Golding Organic & biomolecular chemistry 10 (37), 7610-7617, 2012 | 19 | 2012 |
| The discovery and optimization of benzimidazoles as selective NaV1. 8 blockers for the treatment of pain AD Brown, SK Bagal, P Blackwell, DC Blakemore, B Brown, PJ Bungay, ... Bioorganic & medicinal chemistry 27 (1), 230-239, 2019 | 17 | 2019 |
| Regioselective sulfamoylation at low temperature enables concise syntheses of putative small molecule inhibitors of sulfatases DC Miller, B Carbain, GS Beale, SF Alhasan, HL Reeves, U Baisch, ... Organic & biomolecular chemistry 13 (18), 5279-5284, 2015 | 16 | 2015 |
| Enantioselective synthesis of (R)-and (S)-N-Boc-morpholine-2-carboxylic acids by enzyme-catalyzed kinetic resolution: application to the synthesis of reboxetine analogs PV Fish, M Mackenny, G Bish, T Buxton, R Cave, D Drouard, D Hoople, ... Tetrahedron Letters 50 (4), 389-391, 2009 | 16 | 2009 |
| Identification of a novel ligand for the ATAD2 bromodomain with selectivity over BRD4 through a fragment growing approach DC Miller, MP Martin, S Adhikari, A Brennan, JA Endicott, BT Golding, ... Organic & biomolecular chemistry 16 (11), 1843-1850, 2018 | 15 | 2018 |
| Highly potent and selective chiral inhibitors of PDE5: an illustration of Pfeiffer’s rule ME Bunnage, JP Mathias, A Wood, D Miller, SDA Street Bioorganic & medicinal chemistry letters 18 (23), 6033-6036, 2008 | 15 | 2008 |
| An Alkynylpyrimidine-Based Covalent Inhibitor That Targets a Unique Cysteine in NF-κB-Inducing Kinase I Al-Khawaldeh, MJ Al Yasiri, GG Aldred, C Basmadjian, C Bordoni, ... Journal of Medicinal Chemistry 64 (14), 10001-10018, 2021 | 13 | 2021 |
| (4-phenylimidazol-2-yl) ethylamine derivatives useful as sodium channel modulators SK Bagal, MI Kemp, DC Miller, Y Murata US Patent 9,079,878, 2015 | 13 | 2015 |
| Chemical compounds SK Bagal, AD Brown, MI Kemp, W Klute, LM Sanz, BE Marron, DC Miller, ... US Patent 8,927,587, 2015 | 12 | 2015 |
| New indazole and indolone derivatives and their use pharmaceuticals CM Allerton, D Hepworth, D Miller US Patent App. 11/138,706, 2005 | 12 | 2005 |
| Discovery and optimisation of potent and highly subtype selective Na v 1.8 inhibitors with reduced cardiovascular liabilities SK Bagal, MI Kemp, PJ Bungay, TL Hay, Y Murata, CE Payne, EB Stevens, ... MedChemComm 7 (10), 1925-1931, 2016 | 11 | 2016 |
| Mapping Ligand Interactions of Bromodomains BRD4 and ATAD2 with FragLites and PepLites─ Halogenated Probes of Druglike and Peptide-like Molecular Interactions G Davison, MP Martin, S Turberville, S Dormen, R Heath, AB Heptinstall, ... Journal of Medicinal Chemistry 65 (22), 15416-15432, 2022 | 9 | 2022 |
